In today’s oncology, precision begins at the molecular level. Next-Generation Sequencing (NGS) doesn’t just decode your DNA; it unlocks a complete biological map that helps oncologists target cancer more accurately than ever before. At Neeli Genetics, NGS is integrated into a multi-omic platform that guides powerful immunotherapies like Clavi-Q-RE, bringing personalised, non-toxic, and highly targeted care within reach.
NGS provides deep insights across 4 biological layers of your tumour’s profile:
Together, these data layers fuel the RGCC Onconomics Plus, Oncotrace, and Immune Frame panels, turning test results into personalised action plans.
In 2025, cancer treatment starts not with a guess but with your genetic code. At Neeli Genetics, Next-Generation Sequencing is more than a test; it’s the foundation of personalised, immune-guided, and evidence-based care. You’re not just detecting cancer, and you’re outsmarting it.
India’s leading RGCC diagnostic partner.
Full oncogenetic counselling and care coordination
Integrated genetic, epigenetic, transcriptomic, and proteomic analysis
Certified for Clavi-Q-RE, Q-REstrain, Immune Frame, and Onconomics protocols
Blood draw or biopsy can be arranged at any Neeli Genetics-affiliated clinic or hospital.
Your DNA, RNA, and protein profiles are analysed using RGCC-accredited panels.
You’ll receive a precision oncology report with therapy guidance aligned to global best practices.
Our team helps you and your oncologist translate your results into a personalised treatment plan, often including immunotherapy.
NGS is a powerful diagnostic tool that analyses genetic, epigenetic, transcriptomic, and proteomic information from a blood, tissue, or tumour sample. It helps identify specific mutations and biomarkers that drive cancer, enabling oncologists to create highly personalised and targeted treatment plans.
NGS is suitable for a wide range of cancers, including breast, lung, colorectal, ovarian, and many others. It is especially helpful when selecting targeted therapies or determining eligibility for advanced treatments like Clavi-Q-RE immunotherapy or PARP inhibitors.
Samples can be collected through a blood draw, tissue sample, or tumour biopsy. The exact type and size of the sample may vary depending on the test being conducted and the location of the cancer.
Turnaround time is typically 10–14 days, after which you’ll receive a detailed precision oncology report outlining actionable mutations, therapeutic targets, and potential immunotherapy options.
Neeli Genetics is a leading RGCC diagnostic partner in Hyderabad, India, offering multi-omic profiling across genetic, epigenetic, transcriptomic, and proteomic levels. The results are directly integrated into personalised cancer care plans and immunotherapies like Clavi-Q-RE, ensuring global-standard precision with local access.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
© 2025 Neeli Genetics. All Rights Reserved.